Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM7YVUT)

Drug Name

L-731,988 Drug Info

Synonyms

L-731988; CHEMBL50605; 251922-77-7; AC1Q5RH2; SCHEMBL4936294; AC1L9T44; CTK4F5172; BDBM23399; 4-[1-(4-fluorobenzyl)-1h-pyrrol-2-yl]-2,4-dioxobutanoic acid; 4-[1-[(4-fluorophenyl)methyl]pyrrol-2-yl]-2,4-dioxobutanoic acid; 4-(1-(4-Fluoro-benzyl)-1H-pyrrol-2-yl)-2,4-dioxo-butyric acid; 1H-Pyrrole-2-butanoicacid, 1-[(4-fluorophenyl)methyl]-a,g-dioxo-; 4-{1-[(4-fluorophenyl)methyl]-1H-pyrrol-2-yl}-2,4-dioxobutanoic acid; 1H-Pyrrole-2-butanoic acid, 1-((4-fluorophenyl)methyl)-alpha,gamma-dioxo-

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 475513
CAS Number: CAS 251922-77-7
TTD Drug ID: DM7YVUT

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Human immunodeficiency virus Integrase (HIV IN)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dolutegravir	DMCZGRE	Human immunodeficiency virus infection	1C62	Approved	[2]
Raltegravir	DMYURI6	Human immunodeficiency virus infection	1C62	Approved	[3]
Elvitegravir	DMG9B1U	Human immunodeficiency virus infection	1C62	Approved	[2]
Bictegravir, emtricitabine and tenofovir alafenamide	DMG0H8K	Human immunodeficiency virus infection	1C62	Approved	[4]
GSK1265744	DMT8J0I	Human immunodeficiency virus infection	1C62	Phase 3	[5]
S-1360	DM9KTSG	Human immunodeficiency virus infection	1C62	Phase 2	[6]
S-364735	DMU7ZMH	Human immunodeficiency virus infection	1C62	Phase 2	[7]
C-2507	DMOFT1V	Human immunodeficiency virus infection	1C62	Phase 1	[8]
Acriflavine	DMKVE8X	Human immunodeficiency virus infection	1C62	Phase 1	[9]
S-265744 LAP	DMDQRWT	Human immunodeficiency virus infection	1C62	Phase 1	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Human immunodeficiency virus Integrase (HIV IN)	TT5FH9Y	POL_HV1B1	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Specific inhibition of human immunodeficiency virus type 1 (HIV-1) integration in cell culture: putative inhibitors of HIV-1 integrase. Antimicrob Agents Chemother. 2001 Sep;45(9):2510-6.
2	Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
3	2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9.
4	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
5	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
6	HIV-1 integrase inhibitors: an emerging clinical reality. Drugs R D. 2007;8(3):155-68.
7	The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral. Antimicrob Agents Chemother. 2008 Mar;52(3):901-8.
8	Elvitegravir: a new HIV integrase inhibitor. Antivir Chem Chemother. 2009 Oct 19;20(2):79-85.
9	Why have ten or so nontoxic, retrovirus integrase inhibitors not been made available for AIDS treatment. Biomed Pharmacother. 1999 Dec;53(10):484-6.
10	Long-acting shot prevents infection with HIV analogue. Nature. doi:10.1038/nature.2014.14819. 04 March 2014